– The 11th drug substance facility is released for cGMP operation in the WuXi Biologics’ global manufacturing network. This new facility enhances the company’s capability of providing commercial manufacturing at 4,000L to 20,000L scale, facilitating any project initiation within four…
Related Posts
Messer’s Innovative Cryogenic Solutions are the Ingredient for Growth at IBIE
Processors partner with Messer for a step change in production BRIDGEWATER, N.J., June 6, 2022 /PRNewswire/ — As baked goods…
Marathon Petroleum Corp. Increases Quarterly Dividend
FINDLAY, Ohio, Nov. 1, 2022 /PRNewswire/ — The board of directors of Marathon Petroleum Corp. (NYSE: MPC) has declared a…
MDU Resources Declares Quarterly Dividend on Common Stock
BISMARCK, N.D., Aug. 11, 2022 /PRNewswire/ — MDU Resources Group, Inc.’s (NYSE: MDU) board of directors today declared a quarterly…